U.S. FDA Issues Warning For Contamination At Cadila's India Site
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - U.S. FDA has issued a warning letter to India's Cadila Healthcare Ltd. citing significant violations of current good manufacturing practices at its Sarkhej plant, near the Western city of Ahmedabad. The facility was inspected between Jan.17 and Feb. 3
You may also be interested in...
U.S. FDA Slams Warning Letter On Dr. Reddy's For GMP Violations At Mexico API And Steroids Site
MUMBAI - U.S. FDA issued a warning letter to India's Dr. Reddy's Laboratories Ltd. following investigations that detected adulterated APIs at its Cuernavaca, Mexico site. The regulatory agency noted "significant deviations" from current good manufactuirng practices at the site. The FDA probe centers around unvalidated analytical methods, deficiencies in handling out-of-specification investigations and parameters used to ensure cGMP compliance
Ranbaxy Sees "Progress" On Discussions With U.S. FDA, DOJ; Keeps Lipitor Launch Hopes Alive
MUMBAI - After staying non-committal for several months, Daiichi-Sankyo controlled Ranbaxy Laboratories Ltd. now says it has engaged in wide-ranging negotiations with U.S. FDA and the Department of Justice on multiple issues related to the alleged violation of good manufacturing practices at two of its India-based sites in Paonta Sahib and Dewas
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).